Belarus vs Latin America & Caribbean: Immunization, Hib3
Immunization, Hib3 over time
- Belarus
- Latin America & Caribbean
How they compare
Belarus currently reports 98.0% against 81.8% in Latin America & Caribbean, a difference of 16.2%.
That makes Belarus's figure about 1.2 times Latin America & Caribbean's.
The two have swapped places 1 time across 17 shared years of data; in 2008 it was Latin America & Caribbean ahead.
Belarus ranks 20th and Latin America & Caribbean ranks 22nd of 191 countries.
Across the 3 decades both report, Belarus averaged higher in 1 and Latin America & Caribbean in 2.
Head to head by decade
| Decade | Belarus | Latin America & Caribbean | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 12.5% | 91.3% | 78.8% | Latin America & Caribbean |
| 2010s | 27.3% | 88.0% | 60.7% | Latin America & Caribbean |
| 2020s | 97.8% | 79.0% | 18.8% | Belarus |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher immunization, hib3, Belarus or Latin America & Caribbean?
- Belarus, at 98.0% against 81.8% in Latin America & Caribbean as of 2024.
- What is the difference in immunization, hib3 between Belarus and Latin America & Caribbean?
- 16.2%, with Belarus ahead.
- How many years of comparable data are there for Belarus and Latin America & Caribbean?
- 17 years are reported by both, from 2008 to 2024.
- How do Belarus and Latin America & Caribbean rank globally for immunization, hib3?
- Belarus ranks 20th and Latin America & Caribbean ranks 22nd of 191 countries.
- Where does this data come from?
- WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as Immunization, Hib3 (% of children ages 12-23 months). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Child immunization, Hib3, measures the percentage of children ages 12-23 months who received Hib3 vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against Hib3 after receiving three doses of Haemophilus influenzae type b vaccine.